VERV vs. ATXS, APLT, STTK, ANL, ABUS, KALV, PHAT, OCS, CMPS, and ALT
Should you be buying Verve Therapeutics stock or one of its competitors? The main competitors of Verve Therapeutics include Astria Therapeutics (ATXS), Applied Therapeutics (APLT), Shattuck Labs (STTK), Adlai Nortye (ANL), Arbutus Biopharma (ABUS), KalVista Pharmaceuticals (KALV), Phathom Pharmaceuticals (PHAT), Oculis (OCS), COMPASS Pathways (CMPS), and Altimmune (ALT). These companies are all part of the "pharmaceutical preparations" industry.
Astria Therapeutics (NASDAQ:ATXS) and Verve Therapeutics (NASDAQ:VERV) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, community ranking, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends.
Astria Therapeutics has a net margin of 0.00% compared to Astria Therapeutics' net margin of -1,701.70%. Astria Therapeutics' return on equity of -39.33% beat Verve Therapeutics' return on equity.
Astria Therapeutics currently has a consensus price target of $21.25, indicating a potential upside of 117.50%. Verve Therapeutics has a consensus price target of $33.00, indicating a potential upside of 414.82%. Given Astria Therapeutics' higher possible upside, analysts plainly believe Verve Therapeutics is more favorable than Astria Therapeutics.
Astria Therapeutics has higher earnings, but lower revenue than Verve Therapeutics. Astria Therapeutics is trading at a lower price-to-earnings ratio than Verve Therapeutics, indicating that it is currently the more affordable of the two stocks.
99.0% of Astria Therapeutics shares are owned by institutional investors. Comparatively, 97.1% of Verve Therapeutics shares are owned by institutional investors. 3.4% of Astria Therapeutics shares are owned by company insiders. Comparatively, 21.4% of Verve Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Astria Therapeutics received 536 more outperform votes than Verve Therapeutics when rated by MarketBeat users. Likewise, 72.48% of users gave Astria Therapeutics an outperform vote while only 44.74% of users gave Verve Therapeutics an outperform vote.
Astria Therapeutics has a beta of 0.81, indicating that its share price is 19% less volatile than the S&P 500. Comparatively, Verve Therapeutics has a beta of 1.94, indicating that its share price is 94% more volatile than the S&P 500.
In the previous week, Verve Therapeutics had 4 more articles in the media than Astria Therapeutics. MarketBeat recorded 5 mentions for Verve Therapeutics and 1 mentions for Astria Therapeutics. Verve Therapeutics' average media sentiment score of 0.00 beat Astria Therapeutics' score of -0.31 indicating that Astria Therapeutics is being referred to more favorably in the media.
Summary
Verve Therapeutics beats Astria Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Verve Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VERV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VERV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Verve Therapeutics Competitors List
Related Companies and Tools
